CHICAGO TRUST Co NA Purchases Shares of 2,303 Gilead Sciences, Inc. (NASDAQ:GILD)

CHICAGO TRUST Co NA bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,303 shares of the biopharmaceutical company's stock, valued at approximately $258,000.

Other institutional investors have also added to or reduced their stakes in the company. Range Financial Group LLC raised its stake in shares of Gilead Sciences by 50.1% in the first quarter. Range Financial Group LLC now owns 15,951 shares of the biopharmaceutical company's stock worth $1,787,000 after purchasing an additional 5,325 shares during the last quarter. Portside Wealth Group LLC grew its position in shares of Gilead Sciences by 2.3% during the 1st quarter. Portside Wealth Group LLC now owns 16,834 shares of the biopharmaceutical company's stock valued at $1,886,000 after acquiring an additional 373 shares during the period. Moss Adams Wealth Advisors LLC increased its position in Gilead Sciences by 18.8% in the first quarter. Moss Adams Wealth Advisors LLC now owns 3,700 shares of the biopharmaceutical company's stock worth $415,000 after buying an additional 586 shares during the last quarter. NewSquare Capital LLC increased its holdings in Gilead Sciences by 0.7% in the 1st quarter. NewSquare Capital LLC now owns 56,326 shares of the biopharmaceutical company's stock worth $6,232,000 after acquiring an additional 395 shares during the last quarter. Finally, Park Avenue Securities LLC raised its position in shares of Gilead Sciences by 41.0% in the first quarter. Park Avenue Securities LLC now owns 40,533 shares of the biopharmaceutical company's stock valued at $4,542,000 after purchasing an additional 11,780 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 43,000 shares of company stock valued at $4,630,310 in the last ninety days. Corporate insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GILD shares. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Performance

Shares of GILD traded down $2.91 on Tuesday, reaching $110.09. The company's stock had a trading volume of 8,870,744 shares, compared to its average volume of 7,749,498. The stock's 50 day simple moving average is $105.41 and its two-hundred day simple moving average is $101.80. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $136.94 billion, a P/E ratio of 297.54, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.32) EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.